trending Market Intelligence /marketintelligence/en/news-insights/trending/z8BJc99L3zl3USG83UoNgQ2 content esgSubNav
In This List

Hemispherx Biopharma rebrands as AIM ImmunoTech to reflect cancer focus

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Hemispherx Biopharma rebrands as AIM ImmunoTech to reflect cancer focus

Hemispherx Biopharma Inc. changed its name to AIM ImmunoTech Inc. and its shares will trade under the ticker AIM on the NYSE American, effective Sept. 3.

The Ocala, Fla.-based company has rebranded to reflect its increasing focus on developing immunological agents to treat multiple types of cancer and severe immune-deficiency diseases such as chronic fatigue syndrome.

The company is carrying out various clinical studies on its flagship product rintatolimod, marketed as Ampligen or Rintamod, as a treatment for cancer. The drug is approved in Argentina to treat patients with myalgic encephalomyelitis, or chronic fatigue syndrome, since 2016.

The drug was also awarded orphan-drug status by the U.S. Food and Drug Administration for the same indication.

The NYSE American targets growing companies.